[ad_1]
Findings from a study of 8,517 people in England and Wales, the latest evidence to support the effectiveness of vaccination practices in the UK, writes The Guardian.
Experts found that 96.42 percent. people vaccinated with any vaccine already had antibodies between 28 and 34 days after the first dose.
7-14 days after the second vaccination, this figure reaches 99.08 percent. volunteers in the study.
UCL researchers claim that the antibodies needed to fight COVID-19 are produced by both vaccines.
“This is the first study on the effectiveness of the vaccine in real life, but we are very pleased that the knowledge is simply fantastic,” said Maddie Shrotri, PhD, author of the study findings.
“More than nine out of ten adults in the UK who have received the Pfizer or AstraZeneca vaccine have the necessary antibodies to fight the virus. The antibodies are detected one month after the first vaccination. The effectiveness of these vaccines is simply incredible, especially given the short time they have been developed. This is the most likely victory of science against the worst pandemic of this time “, says the author of the study.
The conclusions are based on 13 thousand. 232 samples for the detection of antibodies from 8517 volunteers in the study. None of them had antibodies in their bodies before the first dose of the vaccine. Anyone with antibodies was forced to withdraw from the study.
The average age of the study participants was 65 years. This figure reflects the fact that older people were the first to get vaccinated against the coronavirus in the country. The vaccination program in the country began on December 8.
The amount of antibodies in the body was initially higher in people who had been vaccinated with Pfizer / BioNTech than with AstraZeneca.
However, four weeks later, both vaccines showed nearly identical antibody levels.
Older people produced fewer antibodies after a vaccine. After the second dose, volunteers of all ages were able to enjoy high levels of antibodies to protect against severe forms of COVID-19.
In addition, the amount of antibodies per vaccine is lower in cases where a person has concomitant diseases such as cancer, diabetes or heart disease, as well as in people taking drugs that suppress the immune response. It is important to note that the difference decreases after the second dose of the vaccine.
“UCL virus surveillance data revealed that the antibody response in the elderly and those with comorbidities was slightly slower after the first dose of the vaccine, but just as strong after the second dose. Our results are another reminder of the importance of the second dose of vaccine. Furthermore, it is further proof that vaccines are the most effective weapon in the fight against a pandemic, ”said Professor Rob Aldridge, who contributed to the study.
Co-authors of the study, whose results have not yet been evaluated by the academic community before publication, say the data should encourage everyone to get vaccinated with both doses of the vaccine, as only then can older people, especially the elderly. elderly and those with comorbid conditions, feel safe.
The number of people vaccinated with both doses of one of those vaccines (or the Moderna vaccine, which only launched in April) currently exceeds 20 million in the UK.
Professor Andrew Hayward, a member of the British government advisory group to advise authorities on the pandemic, also contributed to the study. The study was funded by the National Institutes for Health Research and the British Government Agency for Research and Innovation.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to indicate DELFI as the source.
[ad_2]
